Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105287 · ClinicalTrials.gov registry record · Phase 3
Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
A Phase 3 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00105287: Completed Phase 3 study, sponsored by Cephalon.
NCT00105287 is a Phase 3 study that has completed, run by Cephalon. The registered enrollment target is 100 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00105287, a Phase 3 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.
Interventions
- DRUG OraVescent fentanyl (OVF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
What the finished NCT00105287 record still lists
NCT00105287 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which OraVescent fentanyl (OVF) is the first listed.
NCT00105287 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00105287 about?
NCT00105287 is a clinical study titled "Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients". The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.
What is the current status of trial NCT00105287?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2005-01. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00105287?
The interventions under investigation include: OraVescent fentanyl (OVF) (DRUG).
Who is sponsoring clinical trial NCT00105287?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00105287's enrollment target sits among peer trials
100 1681st of 2000 higher than 288 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia